April - June 2022, Volume 18, Issue 2

Ge J, Wang J, Liu H, Wan R, Yao X

131I Successfully Treated a Case of Hyperthyroidism after Allogeneic Hematopoietic Stem Cell Transplantation

Acta Endo (Buc) 2022, 18 (2): 238-240
doi: 10.4183/aeb.2022.238

Hematopoietic stem cell transplantation (HSCT) is an effective treatment for various types of hereditary hematologic disease, hematological malignancy, primary immunodeficiency and metabolic disease. Thyroid dysfunction is a common complication of HSCT, which situation is mainly manifested as hypothyroidism and rarely as hyperthyroidism. This report presents a 28-yearold man who developed hyperthyroidism 9 years after sibling allogeneic HSCT, which was most likely caused by chronic GVHD. In the meantime, the patient also suffered from liver dysfunction and pancytopenia, for which he was inappropriate to take antithyroid drugs (ATD) for treatment of hyperthyroidism. The patient was orally administered 259 MBq 131I, an individualized dose. The symptoms of hyperthyroidism were mitigated by 131I treatment.

Keywords: Hematopoietic Stem Cell Transplantation, Hyperthyroidism, 131I, graft versus host disease.

Correspondence: Xiaobo Yao MD, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China - Department of Nuclear Medicine, Lujiang Rd 17, Hefei, Anhui, 230032, China, E-mail: xiaobo5327@hotmail.com